© Reuters. FILE PHOTO: Vials labelled “Astra Zeneca COVID-19 Coronavirus Vaccine” and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic
(Reuters) -AstraZeneca said on Thursday its COVID-19 antibody drug was 83% effective in cutting the risk of people contracting symptomatic illness in a six-month follow-up study, cementing the drugmaker’s lead in developing preventative coronavirus treatments.
The Anglo-Swedish company said a separate study in patients with mild-to-moderate COVID-19 showed that a higher dose of the therapy, AZD7442, cut the risk of symptoms worsening by 88% when given within three days of first symptoms.
The latest round of positive results potentially position AstraZeneca (NASDAQ:) as a rare supplier of both COVID-19 vaccines and treatments, with the drugmaker having said the therapy’s “real advantage” was as a preventative shot, rather than as a treatment.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment